<DOC>
	<DOCNO>NCT02454972</DOCNO>
	<brief_summary>A Multicenter Phase II Clinical Trial Lurbinectedin ( PM01183 ) Selected Advanced Solid Tumors assess antitumor activity lurbinectedin ( PM01183 ) term overall response rate ( ORR ) , follow advanced solid tumor small cell lung cancer ( SCLC ) , head neck carcinoma ( H &amp; N ) , neuroendocrine tumor ( NETs ) , biliary tract carcinoma , endometrial carcinoma , carcinoma unknown primary site , germ cell tumor ( GCTs ) , Ewing 's family tumor ( EFTs )</brief_summary>
	<brief_title>Clinical Trial Lurbinectedin ( PM01183 ) Selected Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Age ≥ 18 year . Voluntary sign informed consent ( IC ) Pathologically proven diagnosis follow malignancy : Small cell lung cancer ( SCLC ) . Head neck carcinoma ( H &amp; N ) . Salivary gland tumor exclude . Neuroendocrine tumor ( NETs ) , grade 2 grade 3 accord World Health Organization classification . Biliary tract carcinoma . Endometrial carcinoma . Carcinoma unknown primary site . Germ cell tumor ( GCTs ) , exclude immature teratoma , teratoma malignant transformation . Ewing 's family tumor ( EFTs ) Prior treatment . Patients must receive : SCLC , endometrial carcinoma : one prior chemotherapycontaining line . H &amp; N , NETs , biliary tract , CUP : one two prior chemotherapycontaining line GCTs : limit prior therapy EFTs : two prior chemotherapycontaining line metastatic/recurrent setting . Performance status ≤ 2 [ Eastern Cooperative Oncology Group ( ECOG ) ] Adequate major organ function At least three week since last chemotherapy Women childbearing potential must pregnancy excluded appropriate testing study entry Prior treatment PM01183 trabectedin Prior concurrent malignant disease unless complete remission five year Known central nervous system ( CNS ) involvement Relevant diseases clinical situation may increase patient 's risk Pregnant breastfeed woman fertile patient ( men woman ) use effective method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>